Securities code: 688506 Securities abbreviation: Baili Tianheng Announcement No.: 2025-003

Sichuan Baili Tianheng Pharmaceutical Co., Ltd

In relation to the re-submission of the issuance of overseas listed foreign shares (H shares) to the Hong Kong Stock Exchange

Listing application and publication of application materials

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") is in the process of applying for an overseas public offering of shares (H shares) and listing on the main board of The Stock Exchange of Hong Kong Limited (hereinafter referred to as the "Hong Kong Stock Exchange") (hereinafter referred to as the "Offering").

In accordance with the timing of the offering, the Company has resubmitted to the Hong Kong Stock Exchange on January 21, 2025

The application for the offering was submitted and the application materials for the offering were published on the website of the Hong Kong Stock Exchange on the same day. The application information is prepared and published by the Company in accordance with the requirements of the Securities and Futures Commission of Hong Kong and the Hong Kong Stock Exchange, and is a draft version and the information contained therein may be updated and changed from time to time and investors should not make any investment decisions based on the information contained therein.

In view of the fact that the subscription object of this offering is limited to foreign investors who meet the relevant conditions and domestic qualified investors who have the right to make overseas securities investment in accordance with the relevant laws and regulations of the People's Republic of China, the company will not publish the application materials on the website of the domestic stock exchange and the media that meet the conditions stipulated by the regulatory authorities, but in order to enable domestic investors to keep abreast of the issuance and other relevant information of the company disclosed in the application materials, the inquiry link of the application materials on the website of the Hong Kong Stock Exchange is hereby provided for reference:

Chinese:

https://www1.hkexnews.hk/app/sehk/2025/107104/documents/sehk25012101014_c.pdf

English:

https://www1.hkexnews.hk/app/sehk/2025/107104/documents/sehk25012101015.pdf

It should be noted that this announcement is only made for domestic investors to understand the relevant information of this offering in a timely manner. This announcement and the application materials published on the website of the Hong Kong Stock Exchange do not constitute and shall not be regarded as an offer or solicitation of an offer to any person or entity to acquire, purchase or subscribe for the overseas listed shares (H Shares) issued by the Company.

The Company's application for the offering is subject to the approval and/or approval of the relevant regulatory authorities and stock exchanges such as the Securities and Futures Commission of Hong Kong and the Hong Kong Stock Exchange, and the matter remains uncertain. The company will fulfill its information disclosure obligations in a timely manner according to the progress of the matter, and investors are requested to pay attention to investment risks.

The announcement is hereby made.

Board of Directors of Sichuan Baili Tianheng Pharmaceutical Co., Ltd

January 22, 2025